Site is under construction

en Prognostic Significance of Substance P and Neurokinin-1 Receptor in Bladder Cancer بیوشیمی Biochemistry مقالات اصلی Original Article <div style="text-align: justify;">Background: Bladder cancer is one of the most common genitourinary cancers with significant mortality. Finding reliable tumor markers and potential drug targets can improve early diagnosis, prognosis, and more effective therapeutic protocols. Previous studies have reported the involvement of the substance P (SP)/neurokinin-1 receptor (NK-1R) system in cancers. The potential prognostic role and the interaction of SP and NK-1R in bladder tumor are yet to be elucidated. Methods: Serum samples from 22 primarily diagnosed patients with bladder cancer as well as 22 healthy controls were examined for SP level using ELISA method. Tissue distribution of NK-1R in tumor samples and their adjacent normal tissues was evaluated through immunohistochemistry. esults: Serum SP levels in patients with bladder cancer were higher than the healthy group (p< 0.001) and had a significant correlation with NK-1R staining intensity (p< 0.001), percentage of stained cells (p< 0.001), and NK-1R tissue distribution. Also, the immunoreactivity of NK-1R in cancer samples increased significantly without correlation with tumor characteristics. However, no significant association was found between SP and NK-1R levels with clinical characteristics including tumor size (p= 0.33), tumor stage (p= 0.29), grade (p= 0.93), NK-1R staining intensity (p= 0.53), and percentage of stained cells (p= 0.32). Conclusions: According to our findings, despite the lack of association between SP and NK-1R with clinical characteristics of bladder cancer, their serum levels were higher in patients with bladder cancer. Further studies are needed to confirm the potential prognostic role of SP and NK-1R in bladder cancer.</div> Biomarker, Bladder cancer, Neurokinin-1 receptor, Substance P, Prognosis. 411 420 http://rbmb.net/browse.php?a_code=A-10-861-1&slc_lang=en&sid=1 Elnaz Zahiri 100319475328460016697 100319475328460016697 No Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran & Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. HamidReza Ghorbani 100319475328460016698 100319475328460016698 No Kidney Transplantation Complications Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Ali Moradi 100319475328460016699 100319475328460016699 No Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran & Orthopedic Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Hassan Mehrad-Majd 100319475328460016700 100319475328460016700 No Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. Fariba Mohammadi 100319475328460016701 100319475328460016701 No Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Noorieh Sharifi Sistani 100319475328460016702 100319475328460016702 No Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Seyed Isaac Hashemy hashemyi@mums.ac.ir 100319475328460016703 100319475328460016703 Yes Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran & Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.